Crum Brian T 4

What Happened
Brian T. Crum, SVP, General Counsel & Secretary of Lexicon Pharmaceuticals (LXRX), received two restricted stock unit (RSU) awards on February 12, 2026: 299,710 RSUs and 449,560 RSUs, a total of 749,270 RSUs. Each RSU represents a contingent right to one share of common stock; the Form 4 reports these as derivative awards at $0.00 (compensation awards), not open‑market purchases or sales.

Key Details

• Transaction date: 2026-02-12. Form 4 filed: 2026-02-17 (filed 5 days after the transaction).
• Award amounts: 299,710 RSUs and 449,560 RSUs (total 749,270 RSUs). Reported price: $0.00 (derivative award).
• Vesting (per filing footnotes): each RSU converts to one share when vested; vesting is 1/3 of the RSUs on February 28 of each of the three years following the year of grant.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Footnotes: F1/F2 describe RSU conversion and vesting schedules; F3 (option vesting schedule) appears in the filing but does not apply to these RSU awards.
• Timeliness: Filing appears late relative to the transaction (filed 5 days after the reported date).

Context
This was a compensation award, not a purchase or sale—RSUs typically vest over time and only convert to tradable shares when vested (or subject to company payout terms). Such awards are routine executive compensation and do not by themselves signal an immediate buy/sell decision; the reported $0.00 reflects grant reporting, not market value (actual value will depend on LXRX share price at vesting). The late filing is an administrative detail investors may note for disclosure/timeliness records.